New study aims to uncover why biliary tree cancers behave differently
NCT ID NCT05179486
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study collects tissue and blood samples from 1,500 people with biliary tree cancers, plus healthy volunteers, to look for genetic changes and risk factors. Researchers hope to build models that predict how the cancer develops and responds to treatment. The goal is to better understand the disease, not to test a new therapy.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this research could help doctors better understand what causes biliary tree cancers and why some people respond differently to treatments.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly help participants. It may take years to produce useful results.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 1,500 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2017
- Expected to finish
-
Feb 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with biliary tree cancer and healthy participants
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Pathologically or radiologically confirmed diagnosis of CGC or GBC * With or without prior radiation or chemotherapy * All United States of America (USA) and non USA residents * No age, gender, or racial restriction * Healthy control with no current or history of cancer * Healthy controls are USA and non USA residents * Healthy controls are matched to the cases in age (5 years), gender, and race * Healthy controls are friends and spouses of patients with other than gastro-intestinal (GI) cancers * Chronic Liver Disease (CLD) controls with no current or history of cancer * CLD controls are USA and non USA residents * CLD controls are frequency matched to CGC cases by age (5 years), gender, and race * CLD controls are patients are diagnosed with or without liver biopsy (core or fine needle aspiration) * CLD controls must not have evidence liver cancer diagnosis by computed tomography (CT) or magnetic resonance imaging (MRI) Exclusion Criteria: * None
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cholangiocarcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple score spot hidden gallbladder cancer?
- Can a vaccine stop GI cancers from returning?
- Burning away bile duct blockages: a new weapon against cholangiocarcinoma?
- Can a Three-Drug chemo cocktail before surgery stop biliary tract cancer from coming back?
- Can a targeted drug combo outsmart bile duct cancer?
- Cutting scans, keeping safety: a new streamlined approach to liver cancer treatment